Document -
Proof-of-Concept study in Heart Failure started with anti-inflammatory antibody
The first patient in a new Phase 2 study with Athera lead candidate has been enrolled. The study is planned to run at eleven hospitals and includes myocardial infarction patients with high risk to develop heart failure, who receive either a single dose of the antibody ATH3G10 or placebo.
go to media item
- License:
- Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format: